Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Excellent analysis Canada Fan

<< Previous

Bullboard Posts

Next >>

Comment by m8magicon Dec 04, 2020 8:20am

300 Views

Post# 32035502

RE:RE:RE:Excellent analysis Canada Fan

AcadianWind wrote: I would like to add an odd ball thought to this subject. If this product can "excite and stimulate the immune system", why would all the people of the world ( who could afford to pay for it) not have it as a yearly vaccine to treat any unknown cancer in the body.

Well would it not still have to partner with the administered treatment which would not be given just because a person does not go and get radiation or chemo as a preventative action..

<< Previous

Bullboard Posts

Next >>

dynaCERT leans into global growth with new HydraGEN orders